MLLT10 and leukemia: The Vav-Cre-CALM/AF10-Tg model that has pan hematopoietic expression of the transgene exhibit lymphoma symptoms at 1 year of age, whereas no leukemia developed when the transgene was directed solely to CD19+ B-cells (36).